Entera Reports Robust Preclinical Data for EB612 (Oral LA-PTH(1-34)) for Hypoparathyroidism and EB618 (Oral GLP-1/Glucagon) for Obesity at ENDO 2026

ConferenceEB612EB618Positive

AI Analysis

Summary

Entera reported preclinical data for two oral formulations, EB612 for hypoparathyroidism and EB618 for obesity, presented at ENDO 2026 conference. The announcement marks early-stage progress on novel delivery technologies for hormone therapies.

Outcome Details

Preclinical data presented at ENDO 2026

Importance:4/10

Sentiment:

0.50

preclinicaloral formulationhypoparathyroidismobesityGLP-1ENDO 2026

Related Companies

$ENTXW

Read the original article

Published by yahoo_finance on June 16, 2026 12:33 PM

Read Original